Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
